Rezolute, Inc. (RZLT)
| Market Cap | 130.76M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -56.83M |
| Shares Out | 39.63M |
| EPS (ttm) | -1.10 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 277,914 |
| Open | 3.350 |
| Previous Close | 3.240 |
| Day's Range | 3.240 - 3.487 |
| 52-Week Range | 0.720 - 3.628 |
| Beta | 1.33 |
| Analysts | Strong Buy |
| Price Target | 10.17 (+208.18%) |
| Earnings Date | May 9, 2024 |
About RZLT
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as Ant... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for RZLT stock is "Strong Buy." The 12-month stock price forecast is $10.17, which is an increase of 208.18% from the latest price.
News
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism) Potential to more than double the addr...
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious me...
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
REDWOOD CITY, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious me...
Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism
Company anticipates completing enrollment by the end of 2024 and reporting topline results in mid-year 2025 Company anticipates completing enrollment by the end of 2024 and reporting topline results i...
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious me...
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"
Dallas, Texas--(Newsfile Corp. - November 24, 2023) - Stonegate Healthcare Partners highlights a unique opportunity in its report, "Black Friday Biotech Sale: 12 Stocks for XBI-MAS." Despite overall m...
Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day
REDWOOD CITY, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious me...
Rezolute Reports First Quarter Fiscal 2024 Results
REDWOOD CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious me...
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism PRIME eligibility granted based on key positive data fr...
Rezolute Announces Further Evidence of RZ358's Efficacy in Tumor-Mediated Hyperinsulinism
REDWOOD CITY, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious me...
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023 Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023
Rezolute to Participate in Upcoming Investor Conferences in September
REDWOOD CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential t...
Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism
Study to be initiated in Europe and other ex-US geographies in Q4 2023, with topline results expected 1H 2025 Conference call scheduled today at 4:30 p.m. ET REDWOOD CITY, Calif.
Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease
Dallas, Texas--(Newsfile Corp. - June 1, 2023) - Stonegate Healthcare Partners (SHP), a healthcare strategy consulting firm, is pleased to announce the release of a thematic report that examines innov...
Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress
The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023 The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023
Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
RZ402 is an oral therapy being developed as a potential alternative to anti-vascular growth factor (anti-VEGF) injections into the eye RZ402 is an oral therapy being developed as a potential alternati...
Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert
Conference call and webcast to be held on Wednesday, March 22 at 4:30 pm EDT Conference call and webcast to be held on Wednesday, March 22 at 4:30 pm EDT
Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress
Initiated Phase 2 proof-of-concept study of RZ402
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema
RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye RZ402 is an oral therapy being developed as a potential alternative to invasive a...
Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress
Phase 2 proof-of-concept study of RZ402 expected to be initiated by the end of this year
Rezolute to Present at the Jefferies London Healthcare Conference
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to...
Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting
REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to...
Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress
Announced a $130 million registered direct offering and concurrent private placement priced at-the-market
Rezolute Announces Presentation at the 60th Annual ESPE Meeting
Data from Phase 2b RIZE Study in congenital hyperinsulinism will be presented in oral presentation